Trial data suggest 80% of Zynteglo patients could meet milestones in outcomes-based pricing model

The most recent long-term data for bluebird bio's Zynteglo β thalassemia gene therapy show that about 80% of patients could hit payment milestones based on details the biotech disclosed about its outcomes-based pricing model on Friday.

bluebird bio Inc. (NASDAQ:BLUE) presented long-term follow-up data Friday from the Phase I/II Northstar (HGB-204) trial that showed in 10 β thalassemia patients without the β0/β0 genotype -- in line with Zynteglo's approved indication in Europe -- eight met the primary endpoint of transfusion independence, with the longest duration

Read the full 844 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE